Isolated digital vasculitis in a patient with rheumatoid arthritis: good response to tumour necrosis factor α blocking treatment
Open Access
- 1 May 2001
- journal article
- case report
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 60 (5) , 538-539
- https://doi.org/10.1136/ard.60.5.538
Abstract
Tumour necrosis factor α (TNFα) blocking agents are among the most promising new treatments for rheumatoid arthritis (RA). However, no data exist about the effect of these agents on extra-articular manifestations of RA. A patient is described with small vessel vasculitis that repeatedly responded well to treatment with the soluble p55 TNFα receptor fusion protein Ro 45-2081 (lenercept).Keywords
This publication has 6 references indexed in Scilit:
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Analysis of tumor necrosis factor-alpha production and polymorphisms of the tumor necrosis factor-alpha gene in individuals with a history of Kawasaki diseasePediatrics International, 1999
- Livedo Vasculopathy vs Small Vessel Cutaneous VasculitisArchives of Dermatology, 1998
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- Immunology of systemic rheumatoid diseaseBritish Medical Bulletin, 1995
- In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritisKidney International, 1993